Evidence map›Paper›PMID 35131729›Full record

Trial reportPregnancy hypertension2022

Preconception ovarian reserve and placenta-mediated pregnancy complications among infertile women.

Wendy Vitek, Jinhee Oh, Omar Mbowe, Sally W Thurston, Mindy S Christianson, Aaron K Styer, Alex J Polotsky, Michael P Diamond, Marcelle I Cedars, NIH/NICHD Reproductive Medicine Network

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pregnancy hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Wendy VitekUniversity of Rochester School of Medicine and Dentistry, Rochester, NY, USA. Electronic address: wendy_vitek@urmc.rochester.edu.
Jinhee OhUniversity of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Omar MboweDepartment of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Sally W ThurstonDepartment of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Mindy S ChristiansonJohns Hopkins Medicine, Baltimore, MD, USA.
Aaron K StyerCCRM Fertility Center, Boston, MA, USA.
Alex J PolotskyUniversity of Colorado School of Medicine and SGF Colorado Medical Director, Denver, CO, USA.
Michael P DiamondMedical College of Georgia, Augusta University, Augusta, GA, USA.
Marcelle I CedarsUniversity of California San Francisco Medical Center, San Francisco, CA, USA.
NIH/NICHD Reproductive Medicine Network
University of Rochester · USAugusta University · USJohns Hopkins Medicine · USUniversity of California San Francisco Medical Center · USUniversity of Colorado Denver · US

Funding

TRAINING IN ENVIRONMENTAL HEALTH SCIENCES BIOSTATISTICST32ES007271 · NIEHS · UNIVERSITY OF ROCHESTER · PI Sally W Thurston · 1992 to 2026
$3.9M
The Clinical Research/Reproductive Scientist Training Program (CREST)R25HD075737 · NICHD · UNIVERSITY OF COLORADO DENVER · PI Nanette F. Santoro · 2013 to 2026
$2.3M
NICHD NIH HHS R25 HD075737NIEHS NIH HHS T32 ES007271
6 · The paper itself

Abstract

research questionAre preconception ovarian reserve markers, such as Anti-Mullerian hormone and antral follicle count, associated with preeclampsia and placenta mediated pregnancy complications among women with unexplained infertility who conceive with superovulation?

designThis is a secondary analysis of women with unexplained infertility who had a singleton live birth after enrollment in the Analysis of Multiple Intrauterine Gestations after Ovarian Stimulation (AMIGOS) trial that randomized couples to superovulation with letrozole, clomiphene, or gonadotropins with insemination for up to 4 cycles.

resultsCompared to controls (N = 156), women who developed preeclampsia (N = 17) had lower Anti-Mullerian hormone levels (2.24 ± 1.20 vs. 2.89 ± 2.32, p = 0.07) and lower antral follicle count (18 ± 7.67 vs. 21 ± 11.43, p = 0.16); though these differences were not statistically significant. There was no relationship between Anti-Mullerian hormone (OR: 1.00, 95% CI: 0.76-1.25) or antral follicle count (OR: 0.98, 95% CI 0.93-1.04) with preeclampsia and between Anti-Mullerian hormone (OR: 1.00, 95% CI: 0.83-1.17) and antral follicle count (OR: 1.00, 95% CI: 0.97-1.04) with placenta medicated pregnancy complications after adjusting for age, BMI and race.

conclusionsPreconception ovarian reserve markers are not associated with preeclampsia and placenta mediated pregnancy complications among women with unexplained infertility who conceive with superovulation with insemination.

Indexed as

Ovarian ReserveAdultAnti-Mullerian HormoneFemaleHumansInfant, NewbornInfertility, FemaleLive BirthOvarian FolliclePlacentaPre-EclampsiaPregnancyAnti-Mullerian HormoneAMHAntral follicle countInfertilityOvarian reservePlacenta complicationsPreeclampsia

Identifiers

PMID35131729
PMCPMC8922433
OpenAlexW4210460409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.